Hematolojik hastalıklarda splenektominin mortalite ve morbidite üzerine etkisi
Effects of splenectomy on mortality and morbidity in patients with hematological diseases
View/ Open
Date
2019Author
Pashayeva, Aysel
xmlui.dri2xhtml.METS-1.0.item-emb
2 ayxmlui.mirage2.itemSummaryView.MetaData
Show full item recordAbstract
Introductıon and Purpose: Splenectomy is an important, yet risky, surgical
intervention in patients with certain hematological diseases. Therefore, its benefits
should be weighed against potential complications in individual cases. Most of the
associated risks seem to be as a result of the underlying hematological disease rather
than the procedure itself. In recent years, there is a tendency towards splenic
conservation, which has not only decreased the risk of subsequent Overwhelming
Post-splenectomy Infections (OPSI) but also long-term cardiovascular morbidity. In
this paper, we aim to review the indications and complications of splenectomy
procedure in a hematological patient group at our university hospital.
Patients and Methods: This study is a descriptive analytical study conducted at the
Hematology Outpatient Clinic of Hacettepe University between December 2010 and
January 2018. A total of 111 patients who underwent splenectomy were included in
the study. Patient demographics, indications for splenectomy, co-morbidities,
mortality, and clinical outcome were evaluated. Hematologic diagnostic groups were
compared using Fisher‟s exact tests and Wilcoxon rank-sum tests.
Results: Of the 111 patients included in the study, 62 (55.9%) were female, and a
little over two-thirds (69.4%) were aged 40 years and above. 76 of the participants
(68.5%) had therapeutic splenectomy whereas the remainder underwent splenectomy
for diagnostic purposes. The complication rate post-spelenctomy was 18.9% (21
patients), and the associated mortality rate was 14.5% (16 patients). Of the 16
mortality cases, 6 occured within 2 months after the procedure, all of which had
malignancy. There was a stastistically significant association between early postop
mortality (2 months postop) and performance status (as evaluated using ECOG and
Karnofski performance scores) as well as Charson comorbidity index. Conclusion:
Our study highlighted the safety of splenectomy in most patient groups except for
patients with malignancy. The decision to perform splenectomy should, therefore, be
based on clinical indications and patient needs taking into consideration alternative
strategies reported in ongoing or completed clinical trials.